Yumanity Therapeutics, Inc.
If you purchased Yumanity Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
HALPER SADEH LLP ANNOUNCES INVESTIGATION OF YUMANITY THERAPEUTICS, INC.
June 7, 2022.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating Yumanity Therapeutics, Inc. (NASDAQ: YMTX) in connection with: (1) the sale of its product candidate, YTX-7739, and Yumanity’s unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV for $26 million in cash; and (2) Yumanity’s proposed merger with Kineta, Inc.
The investigation concerns whether Yumanity and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Yumanity shareholders; and (2) disclose all material information necessary for Yumanity shareholders to adequately assess and value the merger consideration. On behalf of Yumanity shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.